Blog

May 23, 2024, 09:20

Yakup Ergün Summarizes Final Results of RIGHT Choice

Yakup Ergün, Medical Oncologist at Ankara Numune Training and Research Hospital, shared a post on X:

“Final results of RIGHT Choice: Ribociclib plus ET vs ChT in premenopausal women with clinically aggressive HR+/HER2− aBC

47.7% patients had investigator-assessed visceral crisis

R+ET vs ChT
mPFS -> 21.8 vs 12.8 mo
ORR -> 66.1% vs 61.8%.”

Proceed to the article.
Source: Yakup Ergün/X
.

aBC Ankara Numune Training and Research Hospital cancer cancer treatment outcomes chemotherapy endocrine therapy HR+/HER2− advanced breast cancer median progression-free survival medical oncologist mPFS OncoDaily Oncology oncology research ORR overall response rate premenopausal women Research Ribociclib RIGHT Choice trial visceral crisis Yakup Ergün

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success

One Hand Gives, Another Takes? Trump, Musk, Congress and Childhood Cancer Research Funding

Fabrice André has been elected as the President of the ESMO for the term 2025-2026

Special Coverage